Prevalence and Clinical Features of Community-Acquired Pneumonia Caused by Macrolide-Resistant Mycoplasma pneumoniae Isolated from Adults in Jeju Island
- PMID: 30484744
- DOI: 10.1089/mdr.2018.0295
Prevalence and Clinical Features of Community-Acquired Pneumonia Caused by Macrolide-Resistant Mycoplasma pneumoniae Isolated from Adults in Jeju Island
Abstract
Aims: Although the cases of macrolide-resistant Mycoplasma pneumoniae (MRMP) have been increasing substantially among children, there are very few studies that have focused on MRMP in adults. This study aimed to investigate the prevalence and clinical features of community-acquired pneumonia (CAP) caused by MRMP from adults in Jeju Island, Korea. Methods: We retrospectively recruited adult patients with CAP in whom M. pneumoniae infections had been confirmed for a 7-year period. Macrolide resistance was determined by identifying a mutation in the 23S rRNA gene using PCR. Results: In total, 70 subjects were included. Their mean age was 46.1 years and 36 (51.4%) were women. Only two isolates (2.9%) carried macrolide resistance mutations in the 23S rRNA gene, and all the mutations were A2063G transitions. No significant differences were observed in age, comorbidities, symptoms, duration of fever, and length of hospital stay between the MRMP and macrolide-sensitive Mycoplasma pneumoniae groups. The number of involved pulmonary lobes was greater in the MRMP group (3.50 vs. 1.44, p = 0.008). Conclusion: The prevalence of CAP caused by MRMP was relatively low in adults in Jeju Island. Patients with MRMP pneumonia tended to have multilobar pneumonic infiltrates.
Keywords: drug resistance; macrolides.
Similar articles
-
Clinical Characteristics of Macrolide-Resistant Mycoplasma pneumoniae from Children in Jeju.J Korean Med Sci. 2017 Oct;32(10):1642-1646. doi: 10.3346/jkms.2017.32.10.1642. J Korean Med Sci. 2017. PMID: 28875608 Free PMC article.
-
Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.J Clin Microbiol. 2019 Oct 23;57(11):e00968-19. doi: 10.1128/JCM.00968-19. Print 2019 Nov. J Clin Microbiol. 2019. PMID: 31484701 Free PMC article.
-
[Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China].Zhonghua Jie He He Hu Xi Za Zhi. 2013 Dec;36(12):954-8. Zhonghua Jie He He Hu Xi Za Zhi. 2013. PMID: 24503430 Chinese.
-
Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance.Clin Respir J. 2017 Jul;11(4):419-429. doi: 10.1111/crj.12379. Epub 2015 Oct 13. Clin Respir J. 2017. PMID: 26365811 Review.
-
Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.World J Pediatr. 2024 Sep;20(9):901-914. doi: 10.1007/s12519-024-00831-0. Epub 2024 Aug 14. World J Pediatr. 2024. PMID: 39143259 Free PMC article. Review.
Cited by
-
Recent Macrolide Resistance Pattern of Mycoplasma Pneumonia in the World: A Systematic Review and Meta-Analysis.Iran J Public Health. 2025 Mar;54(3):530-541. doi: 10.18502/ijph.v54i3.18246. Iran J Public Health. 2025. PMID: 40330176 Free PMC article. Review.
-
Efficacy of Azithromycin plus Glucocorticoid Adjuvant Therapy on Serum Inflammatory Factor Levels and Incidence of Adverse Reactions in Children with Mycoplasma Pneumonia.Evid Based Complement Alternat Med. 2022 Apr 4;2022:1207512. doi: 10.1155/2022/1207512. eCollection 2022. Evid Based Complement Alternat Med. 2022. Retraction in: Evid Based Complement Alternat Med. 2023 Dec 13;2023:9819502. doi: 10.1155/2023/9819502. PMID: 35419069 Free PMC article. Retracted.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous